Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): Interim safety and efficacy results from a phase 1 study Meeting Abstract
| Authors: | Budde, L. E.; Sehn, L. H.; Assouline, S.; Flinn, I. W.; Isufi, I.; Yoon, S. S.; Kim, W. S.; Matasar, M. J.; Nastoupil, L. J.; Santiago, R.; Koh, Y.; Hernandez, G.; Li, C. C.; Kulkarni, P. R.; McCall, B.; McClellan, S.; Yin, S.; Gupta, V.; Chu, Y. W.; Bartlett, N. L. |
| Abstract Title: | Mosunetuzumab, a full-length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL): Interim safety and efficacy results from a phase 1 study |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837601108 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-118344 |
| Notes: | Meeting Abstract : 399 -- Source: Wos |
